• Publications
  • Influence
Modulation of the blood-brain barrier in oncology: therapeutic opportunities for the treatment of brain tumours?
TLDR
Since P-glycoprotein in the BBB restricts the brain entry of many anticancer drugs, inhibition of this drug transporter may be an option for improved drug delivery to brain tumours. Expand
Increased penetration of paclitaxel into the brain by inhibition of P-Glycoprotein.
TLDR
The efficacy of several (putative) inhibitors of Pgp (cyclosporin A, PSC833, GF120918, and Cremophor EL) on the penetration of paclitaxel into the mouse brain is determined and it is warranted to test pac litaxel in combination with GF 120918 in experimental brain tumor models and in clinical trials. Expand
Improved penetration of docetaxel into the brain by co-administration of inhibitors of P-glycoprotein.
TLDR
All three inhibitors of P-glycoprotein inhibit Pgp in the blood-brain barrier and elacridar increases the accumulation of docetaxel in the brain without significant effects on systemic exposure. Expand
The influence of the P-glycoprotein inhibitor zosuquidar trihydrochloride (LY335979) on the brain penetration of paclitaxel in mice
TLDR
Zosuquidar·3HCl is only moderately active as an inhibitor of P-gp at the blood-brain barrier and the concentrations in plasma and tissues have already declined to levels insufficient to inhibit P- gp at theBlood- brain barrier. Expand
Effect of Vegan Fecal Microbiota Transplantation on Carnitine‐ and Choline‐Derived Trimethylamine‐N‐Oxide Production and Vascular Inflammation in Patients With Metabolic Syndrome
TLDR
Single lean vegan‐donor fecal microbiota transplantation in metabolic syndrome patients resulted in detectable changes in intestinal microbiota composition but failed to elicit changes in TMAO production capacity or parameters related to vascular inflammation. Expand
Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial
TLDR
In this small exploratory phase 2 part of the PANAMO trial, C5a inhibition with IFX-1 appears to be safe in patients with severe COVID-19 and several patients could not be assessed regularly in the supine position because of severe hypoxaemia. Expand
A simple and sensitive assay for the quantitative analysis of paclitaxel in human and mouse plasma and brain tumor tissue using coupled liquid chromatography and tandem mass spectrometry.
TLDR
Validation results indicate that calibration standards in human plasma can be used to quantify paclitaxel in all tested matrices, and the method can be applied to studies generating only small sample volumes, but also to studies inhuman plasma requiring a lower limit of quantitation. Expand
Towards evidence‐based pharmacotherapy in children
TLDR
The goals of this paper are to review the current problems in daily practice and to address the needs for evidence based pharmacotherapy in children. Expand
Development of luciferase tagged brain tumour models in mice for chemotherapy intervention studies.
TLDR
Intacranial tumour models in mice featuring intact or locally disrupted BBB properties, which can be used in testing chemotherapy against brain tumours are developed and will be useful for chemotherapeutic intervention studies. Expand
Cholic acid therapy in Zellweger spectrum disorders
TLDR
Oral cholic acid therapy can be used in the majority of patients with a ZSD, leading to at least partial suppression of bile acid synthesis, however, caution is needed in patients with advanced liver disease due to possible hepatotoxic effects. Expand
...
1
2
3
4
5
...